{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-050329","form_type":"8-K","ticker":"ESLA","cik":"0001844417","company_name":"Estrella Immunopharma, Inc.","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.102498+00:00","generated_at":"2026-05-20T01:54:01.647411+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share","bullets":["Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).","Net proceeds to fund Phase I STARLIGHT-1 trial of EB103 CD19-targeted T-cell therapy in NHL.","True-Up provision: additional shares if 12-month closing price below $1.50 (floor $0.20).","Company agreed to file resale registration statement for shares issued in PIPE.","Closing subject to customary conditions; investor support cited as confidence in ARTEMIS platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-050329","json":"https://secwatch.observer/filing/0001213900-25-050329.json","markdown":"https://secwatch.observer/filing/0001213900-25-050329.md","text":"https://secwatch.observer/filing/0001213900-25-050329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025050329/0001213900-25-050329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1844417/000121390025050329/ea0244428-8k_estrella.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T01:54:01.647411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}